Dr. Reddy's Laboratories records $2.2 billion in annual sales, up 14%

HYDERABAD, India — Dr. Reddy’s Laboratories on Tuesday posted $2.2 billion in annual sales for the fiscal year ended March 31, representing growth of 14%.

The company launched 54 new generic products and filed 51 new product registrations and 61 Drug Master Files globally in fiscal year 2014.

Revenues from the company's global generics segment totaled $1.8 billion, with year-on-year growth of 27%, primarily driven by North America and emerging markets. Revenues from North America for fiscal year 2014 totaled more than $900 million with year-on-year growth of 46%. Growth was largely driven by key launches with limited competition. Nine new products were launched during the year, including azacitidine, decitabine, zoledronic acid, donepezil 23mg and divalproex ER.

Cumulatively, Dr. Reddy's Laboratories has 62 ANDAs pending for approval with the Food and Drug Administration, of which 39 are Paragraph IVs, out of which nine have ‘First To File’ status.